Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, U.S.A.
Department of Otolaryngology-Head and Neck Surgery, West Virginia University, Morgantown, West Virginia, U.S.A.
Laryngoscope. 2020 Jun;130(6):1414-1421. doi: 10.1002/lary.28100. Epub 2019 Jun 13.
To determine factors affecting outcomes for patients with sinonasal and nasopharyngeal adenoid cystic carcinoma (SNACC) treated using the endoscopic endonasal approach (EEA) with preservation of key structures followed by adjuvant radiotherapy (RT).
Retrospective case series of 30 patients treated at the University of Pittsburgh between 2000 and 2014. Hospital records were reviewed for clinical and pathologic data. Outcome measures included overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) rates.
The majority of patients had T4a and T4b disease (23.3%, and 63.3%). Microscopically positive margins were present in 21 patients (63.6%). Positive margins were present in nine patients (30.0%). The mean and median follow-up were 3.97 and 3.29 years. Five-year OS, DFS, LRFS, and DMFS were 62.66%, 58.45%, 87.54%, and 65.26%. High-/intermediate-grade tumors had worse DFS (P = .023), and LRFS (P = .026) (HR = 4.837, 95% CI, 1.181-19.812). No factors were associated with significantly worse DMFS. No patient suffered CSF leak, optic nerve, or internal carotid injury. The mean and median length of hospital stay was 4.1 days and 2.0 days (range: 0-32 days).
Organ-preserving EEA with adjuvant RT for low-grade SNACC offers 5-year survival similar to that reported by other studies, which include radical, open skull base surgery. Patients with high-grade disease do poorly and may benefit from novel treatment strategies. For low-grade disease, organ-preserving EEA with RT may be the best option, offering a balance of survival, quality of life, and decreased morbidity for patients with this difficult-to-cure disease.
4 Laryngoscope, 130:1414-1421, 2020.
确定采用内镜经鼻入路(EEA)保留关键结构并辅以辅助放疗(RT)治疗的鼻腔鼻窦和鼻咽腺样囊性癌(SNACC)患者的结局影响因素。
这是匹兹堡大学 2000 年至 2014 年间治疗的 30 例患者的回顾性病例系列研究。对医院记录进行了临床和病理数据的回顾。主要观察指标包括总生存率(OS)、无疾病生存率(DFS)、局部无复发生存率(LRFS)和无远处转移生存率(DMFS)。
大多数患者患有 T4a 和 T4b 疾病(分别为 23.3%和 63.3%)。21 例患者(63.6%)存在显微镜下阳性切缘。9 例患者(30.0%)存在阳性切缘。平均和中位随访时间分别为 3.97 年和 3.29 年。5 年 OS、DFS、LRFS 和 DMFS 分别为 62.66%、58.45%、87.54%和 65.26%。高/中级别肿瘤的 DFS 较差(P =.023),LRFS 较差(P =.026)(HR = 4.837,95%CI,1.181-19.812)。没有因素与 DMFS 显著恶化相关。没有患者发生脑脊液漏、视神经或颈内动脉损伤。平均和中位住院时间分别为 4.1 天和 2.0 天(范围:0-32 天)。
低级别 SNACC 采用保留器官的 EEA 联合辅助 RT 治疗,其 5 年生存率与其他包括根治性、开放性颅底手术的研究相似。高级别疾病患者预后较差,可能受益于新的治疗策略。对于低级别疾病,保留器官的 EEA 联合 RT 可能是最佳选择,为这种难以治愈的疾病患者提供了生存、生活质量和降低发病率之间的平衡。
4 级喉镜,130:1414-1421,2020 年。